Article Details

Purple Biotech Granted New U.S. Patent for NT219 in - GlobeNewswire

Retrieved on: 2025-03-05 12:38:01

Tags for this article:

Click the tags to see associated articles and topics

Purple Biotech Granted New U.S. Patent for NT219 in - GlobeNewswire. View article details on hiswai:

Summary

The article highlights Purple Biotech's Phase 2 study on NT219, in combination with cetuximab, for head and neck cancer, advancing biotech solutions against immune evasion and drug resistance. It's centered on EGFR involvement and located in Rehovot, Israel.

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo